The AJMC® clinical page includes all the published content across AJMC.com, The American Journal of Managed Care® and Evidence-Based Oncology™ on a variety of specialties, including dermatology, cardiology, oncology, and rheumatology.
April 28th 2025
From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ground.
Interview: Real-World Data Show Daratumumab 1L Improves OS in Some Patients With MM
January 11th 2022For patients with multiple myeloma (MM) who are not eligible for transplant, should novel treatments be used right away? Or should clinicians save the best potential therapies for relapses, which are inevitable with this disease?
Read More
Real-World Data Highlight Efficacy, Safety of Combination Treatment for Chronic Migraine
January 10th 2022A combination of onabotulinumtoxinA and a calcitonin gene-related peptide monoclonal antibody appears effective and safe in patients with chronic migraine, according to real-world data.
Read More
Targeted Cancer Therapies Showing Promise in Treating Parenchymal Brain Metastases
January 10th 2022Recent learnings about treating parenchymal brain metastases stem from several solid tumors, most commonly non-small cell lung cancer, breast cancer, and melanoma, all of which have benefitted from targeted treatments in recent years.
Read More
COVAX Data Show Similar COVID-19 Vaccine Safety Between General Public, Patients With RMD
January 7th 2022The safety profiles of COVID-19 vaccines in patients with inflammatory rheumatic and musculoskeletal disease (RMD) was comparable with patients with non-inflammatory RMD and the general population, according to a new study.
Read More
Molecular Profiling Identifies Potential Prognostic Biomarker for Treatment Response in HNSCC
January 6th 2022Human papillomavirus surrogate marker p16 was identified as a potential prognostic biomarker for standard-of-care immune checkpoint blockade therapy response in non-oropharyngeal head and neck squamous cell carcinoma.
Read More
Ponatinib, High-Dose Chemo Combo Likely to Benefit High-risk BP-CML
January 1st 2022Survival rates for patients with blast-phase chronic myeloid leukemia (BP-CML) are notoriously poor, necessitating effective treatments to fill the care gap for this group who often survive less than 1 year.
Read More